Cyclana Bio May 19 2026 Cyclana Bio, a biotechnology company pioneering tissue-level approaches to women’s health, today announced it has received Health Research Authority (HRA) and Research Ethics Committee (REC) approval for its 500-patient clinical observational study, PEMP (Predicting Endometriosis Mechanisms and Populations). The first patients to take part in the study have been recruited at Peterborough City Hospital, with the Rosie Hospital, Cambridge recently also starting recruitment.